Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Allogeneic Cardiosphere-Derived Cells (CAP-1002), Deramiocel (CAP-1002), CAP-1002, CDCs
Allogeneic Cardiosphere-Derived Cells · 4 trials · 11 indications
| Name | Type | Description |
|---|---|---|
| CAP-1002 | BIOLOGICAL | Peripheral infusion of 150 million cardiosphere-derived cells (CDCs) |
| Placebo | BIOLOGICAL | Matching placebo solution |
| Allogeneic Cardiosphere-Derived Cells (CAP-1002) | BIOLOGICAL | Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs) |
Allogeneic Cardiosphere-Derived Cells is an investigational cell therapy being studied for Duchenne Muscular Dystrophy, specifically to address cardiomyopathy associated with the disease. It is being developed by Capricor Therapeutics, Inc. under the ticker CAPR. The therapy is in Phase 2 clinical development.
Allogeneic Cardiosphere-Derived Cells is developed by Capricor Therapeutics, Inc., which trades under the ticker CAPR. The company is advancing this cell therapy for Duchenne Muscular Dystrophy and related cardiomyopathy.
Allogeneic Cardiosphere-Derived Cells is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. Two Phase 2 trials have been completed, and there are currently no active trials listed for this asset.
Allogeneic Cardiosphere-Derived Cells has been evaluated in two completed Phase 2 trials. The HOPE-Duchenne trial, NCT02485938, enrolled 25 participants with Duchenne Muscular Dystrophy and cardiomyopathy. The HOPE-OLE trial, NCT06304064, enrolled 8 participants with Duchenne Muscular Dystrophy. Both trials are completed.
Yes, Allogeneic Cardiosphere-Derived Cells is also known as CAP-1002. CAP-1002 is the shorthand name used for this investigational cell therapy developed by Capricor Therapeutics, Inc. for Duchenne Muscular Dystrophy.